FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 357:1579-1588 October 18, 2007 Number 16 Next

	Full Text PDF PDA Full Text PowerPoint Slide Set CME Exam Editorial by Runowicz, C. D. Letters Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited E-mail When Letters Appear PubMed Citation

ABSTRACT

Background To determine whether testing for DNA of oncogenic human papillomaviruses (HPV) is superior to the Papanicolaou (Pap) test for cervical-cancer screening, we conducted a randomized trial comparing the two methods.

Methods We compared HPV testing, using an assay approved by the Food and Drug Administration, with conventional Pap testing as a screening method to identify high-grade cervical intraepithelial neoplasia in women ages 30 to 69 years in Montreal and St. John's, Canada. Women with abnormal Pap test results or a positive HPV test (at least 1 pg of high-risk HPV DNA per milliliter) underwent colposcopy and biopsy, as did a random sample of women with negative tests. Sensitivity and specificity estimates were corrected for verification bias.

Results A total of 10,154 women were randomly assigned to testing. Both tests were performed on all women in a randomly assigned sequence at the same session. The sensitivity of HPV testing for cervical intraepithelial neoplasia of grade 2 or 3 was 94.6% (95% confidence interval [CI], 84.2 to 100), whereas the sensitivity of Pap testing was 55.4% (95% CI, 33.6 to 77.2; P=0.01). The specificity was 94.1% (95% CI, 93.4 to 94.8) for HPV testing and 96.8% (95% CI, 96.3 to 97.3; P<0.001) for Pap testing. Performance was unaffected by the sequence of the tests. The sensitivity of both tests used together was 100%, and the specificity was 92.5%. Triage procedures for Pap or HPV testing resulted in fewer referrals for colposcopy than did either test alone but were less sensitive. No adverse events were reported.

Conclusions As compared with Pap testing, HPV testing has greater sensitivity for the detection of cervical intraepithelial neoplasia. (Current Controlled Trials number, ISRCTN57612064 [controlled-trials.com] .)

Source Information

From the Departments of Oncology and Epidemiology & Biostatistics (M.-H.M., J.H., F.C., E.L.F.), Family Medicine (E.D.-F.), and Pathology (A.F.), McGill University, Montreal; the Départements d'Obstétrique-Gynécologie (M.-H.M.) and de Médecine Familiale (I.R.), Université de Montréal, Montreal; the Department of Clinical Epidemiology and Biostatistics, McMaster University, Hamilton, ON (S.D.W.); the Sir Mortimer B. Davis–Jewish General Hospital, Montreal (A.F.); the Newfoundland Public Health Laboratory, St. John's (S.R.); and the Département de Microbiologie–Infectiologie, Hôpital Notre-Dame du Centre Hospitalier de l'Université de Montréal, Montreal (F.C.) — all in Canada.

Address reprint requests to Dr. Franco at the Division of Cancer Epidemiology, McGill University, 546 Pine Ave. W., Montreal, QC H2W 1S6, Canada, or at eduardo.franco{at}mcgill.ca.

Full Text of this Article

Related Letters:

Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer
Lytwyn A., Elit L., Sellors J. W., Lin B. T., Frank A. P., Berkhof J., Meijer C. J., Fields R. P., Franco E. L., Mayrand M.-H., Ratnam S., the Canadian Cervical Cancer Screening Trial Study Group , Runowicz C. D.
Extract | Full Text | PDF  
N Engl J Med 2008; 358:641-644, Feb 7, 2008. Correspondence

This article has been cited by other articles:

• Castle, P. E. (2008). Invited Commentary: Is Monitoring of Human Papillomavirus Infection for Viral Persistence Ready for Use in Cervical Cancer Screening?. Am J Epidemiol 0: kwn037v1-kwn037 [Abstract] [Full Text]  
• Gravitt, P. E., Schiffman, M., Solomon, D., Wheeler, C. M., Castle, P. E. (2008). A Comparison of Linear Array and Hybrid Capture 2 for Detection of Carcinogenic Human Papillomavirus and Cervical Precancer in ASCUS-LSIL Triage Study. Cancer Epidemiol. Biomarkers Prev. 17: 1248-1254 [Abstract] [Full Text]  
• Ronco, G., Giorgi-Rossi, P., Carozzi, F., Confortini, M., Palma, P. D., Del Mistro, A., Gillio-Tos, A., Minucci, D., Naldoni, C., Rizzolo, R., Schincaglia, P., Volante, R., Zappa, M., Zorzi, M., Cuzick, J., Segnan, N., On behalf of the New Technologies for Cervical Can, (2008). Results at Recruitment From a Randomized Controlled Trial Comparing Human Papillomavirus Testing Alone With Conventional Cytology as the Primary Cervical Cancer Screening Test. JNCI J Natl Cancer Inst 100: 492-501 [Abstract] [Full Text]  
• Kiviat, N. B., Hawes, S. E., Feng, Q. (2008). Screening for Cervical Cancer in the Era of the HPV Vaccine--The Urgent Need for Both New Screening Guidelines and New Biomarkers. JNCI J Natl Cancer Inst 100: 290-291 [Full Text]  
• Lytwyn, A., Elit, L., Sellors, J. W., Lin, B. T., Frank, A. P., Berkhof, J., Meijer, C. J., Fields, R. P., Franco, E. L., Mayrand, M.-H., Ratnam, S., the Canadian Cervical Cancer Screening Trial Study, , Runowicz, C. D. (2008). Human Papillomavirus DNA versus Papanicolaou Screening Tests for Cervical Cancer. NEJM 358: 641-644 [Full Text]  
• Lippman, A., Boscoe, M., Scurfield, C. (2008). Do you approve of spending $300 million on HPV vaccination?: NO. cfp 54: 175-177 [Full Text]  
• (2007). HPV DNA vs. Pap Screening Tests for Cervical Cancer. JWatch Oncology and Hematology 2007: 3-3 [Full Text]  
• Runowicz, C. D. (2007). Molecular Screening for Cervical Cancer -- Time to Give up Pap Tests?. NEJM 357: 1650-1653 [Full Text]  
• (2007). Is HPV Testing Better Than the Pap Smear?. JWatch Women's Health 2007: 1-1 [Full Text]  
• (2007). Can Human Papillomavirus Testing Replace the Pap Smear?. JWatch General 2007: 2-2 [Full Text]